Bernstein on Eli Lilly (LLY): 'Our Top Pick With $1300 PT'

Bernstein SocGen Group analyst Courtney Breen reiterated an Outperform rating and $1,300.00 price target on Eli Lilly (NYSE: LLY).

The analyst commented: "2026 is all about the oral opportunity, ex-US & diabetes expansion to hit in 2027; with an increasing need as move toward the end of this decade for the beyond-incretin pipeline to show-up & demonstrate the next leg of growth. We like the foundations & see this year set-up for upside surprises - our top pick with $1300 PT."

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $1038.40 yesterday.

You May Also Be Interested In

• Freedom Broker Downgrades Flexsteel (FLXS) to Hold
• BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
• UBS Downgrades Core Natural Resources (CNR) to Neutral